Up­dat­ed: FDA ap­proves Roche's new treat­ment for sub­set of breast can­cer pa­tients

The FDA has ap­proved Roche’s in­avolis­ib plus Pfiz­er’s Ibrance and ful­ves­trant in a sub­type of breast can­cer over a month be­fore the tar­get ac­tion date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA